Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | mRNA-2752 |
Synonyms | |
Therapy Description |
mRNA-2752 is a lipid nanoparticle encapsulated combination of messenger RNAs encoding IL-36gamma, IL-23, and OX40L (TNFSF4), which stimulate the immune system (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
mRNA-2752 | mRNA2752|mRNA 2752 | mRNA-2752 is a lipid nanoparticle encapsulated combination of messenger RNAs encoding IL-36gamma, IL-23, and OX40L (TNFSF4), which stimulate the immune system (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03739931 | Phase I | mRNA-2752 mRNA-2752 + Tremelimumab Durvalumab + mRNA-2752 | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies | Active, not recruiting | USA | ISR | AUS | 0 |